chf

Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that is hydrolysed to the active diacid trandolaprilat.

CHF-4227 is a novel, potent and selective estrogen receptor modulator that reduces cholesterol and LDL cholesterol concentrations.

CHF-6333 CATION is a compound that inhibits human neutrophil elastase.

CHF-6333 is an inhibitor targeting human neutrophil elastase.

CHF-6550 is an antagonist of the muscarinic M3 receptor (M3 receptor) and an agonist of the β2 adrenoceptor (β2 adrenoceptor), with pKi values of 9.3 and 10.6, respectively. It exhibits favorable hepatocyte clearance in rat models and demonstrates good pharmacokinetic properties in guinea pigs.

CHF 1255 is a potential drug for the treatment of heart failure.

CHF 2819 is a novel orally active acetylcholinesterase inhibitor (AChE) developed for the treatment of Alzheimer's disease (AD). CHF 2819 is a selective inhibitor of AChE, it is 115 times more potent against this enzyme than against butyrylcholinesterase (BuChE).

CH-5137291 is a pure AR antagonist with AR nuclear translocation inhibition activity. It inhibits castration and prevents the growth of prostate cancer cells.

CHF-2993 is a bio-active chemical.

CHF-5022 is a nonsteroidal anti-inflammatory drug that selectively inhibits the production of beta-amyloid protein (1-42) (ABETA42).

CHF-6366 is a dual-action chemical compound acting as a potent M3 muscarinic antagonist and β2-adrenergic receptors agonist, with respective pK i values of 10.4 and 11.4. Additionally, it exhibits weak calcium channel inhibitory properties (IC 50 ~50 μM) and demonstrates the ability to inhibit bronchoconstriction in guinea pigs, making it a viable candidate for chronic obstructive pulmonary disease (COPD) research.

CHF-2060 is a novel acetylcholinesterase inhibitor.

CHF-6523 is a PI3K δ inhibitor that can be used in research related to chronic obstructive pulmonary disease (COPD).

CHF5407(SVT-47060) is a potent and selective muscarinic M3 receptor antagonist with prolonged action at muscarinic receptors.CHF5407 has an effect on bronchospasm and may be used in the study of respiratory disorders.CHF5407 is a potent and selective muscarinic M3 receptor antagonist with prolonged action at muscarinic receptors.

FCHFHS-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity[1].

Nolomirole is a dopamine receptor agonist that reduces symptoms of congestive heart failure caused by monoclinine.

Nolomirole HCl (CHF 1035) is a novel selective dopamine agonist with oral activity and inhibitory effects on norepinephrine release, which can be used to study mild chronic heart failure.

Tanimilast (CHF-6001) is a novel, potent, and selective phosphodiesterase 4 inhibitor with an IC50 value of 0.026 ± 0.006 nM. It exhibits potent anti-inflammatory activity and is indicated for topical use in the lungs. Tanimilast was studied for its effects on obstructive lung disease.

Trandolapril D5 is a deuterium labeled Trandolapril. Trandolapril is an orally active inhibitor of angiotensin converting enzyme (ACE) for hypertension and congestive heart failure (CHF).

Candesartan (CV 11974) is an angiotensin II receptor blocker widely used in the treatment of hypertension and heart failure.

Itanapraced (CHF5074), a γ-secretase modulator, reduces Aβ42/40 secretion (IC50: 3.6/18.4 μM).

Indantadol HCl (CHF-3381) is a NMDA antagonist and nonselective MAO inhibitor.

BMS-193884 is an oral endothelin antagonist for the treatment of congestive heart failure (CHF) and pulmonary arterial hypertension.

Nebentan (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan . Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively[1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo[2]. Nebentan inhibits the specific binding of [125I] endothelin-1 to endothelin ETA and ETB receptors in a concentration dependent manner,Ki values are 0.697 nM and 1.53 nM for human and rat endothelin ETA receptors, respectively. In contrast, YM598 exhibits low affinities for human and rat endothelin ETB receptors, with Ki values of 569 nM and 155 nM,respectively[1].In measurement of intracellular Ca2+ concentration, Nebentan concentration-dependently inhibits the increase in [Ca2+]i induced by 10 nM endothelin-1 in both CHO cells and A10 cells, the IC50 values are 26.2 nM for CHO cells and 26.7 nM for A10 cells, respectively[1]. Nebentan (oral administration; 0.1-1 mg/kg; 4 weeks) significantly inhibits the progression of pulmonary hypertension and the development of right ventricular hypertrophy[2].Nebentan (oral administration; 1 mg/kg; 30 weeks) significantly ameliorates the poor survival rate of CHF rats, it markedly reduces the hypertrophy of both ventricles as well as pulmonary congestion[2]. [1]. Hironori Yuyama, et al. Pharmacological Characterization of YM598, an Orally Active and Highly Potent Selective Endothelin ET(A) Receptor Antagonist. Eur J Pharmacol. 2003 Sep 30;478(1):61-71. [2]. Akira Fujimori, et al. YM598, an Orally Active ET(A) Receptor Antagonist, Ameliorates the Progression of Cardiopulmonary Changes and Both-Side Heart Failure in Rats With Cor Pulmonale and Myocardial Infarction. J Cardiovasc Pharmacol. 2004 Nov;44 Suppl 1:S354-7.